Mirena (Levonorgestrel)

Levonorgestrel released from Mirena binds to progesterone receptors in the endometrium, causing the lining to become thin and less receptive to implantation. It also thickens cervical mucus, hindering sperm movement, and may suppress ovulation in some users. These combined actions create a contraceptive environment while also reducing menstrual blood loss.

Mirena contains a total of 52 mg of levonorgestrel and is designed to release approximately 20 µg of hormone per day. The device is inserted by a qualified health professional and provides contraceptive protection for up to five years. Exact dosing and replacement intervals are determined by the prescribing clinician.

Mirena is classified as Pregnancy Category X, meaning it must not be used in women who are pregnant or who intend to become pregnant. If pregnancy occurs, the device should be removed promptly. Limited data suggest that levonorgestrel exposure through breast milk is low, but clinicians usually advise caution and assess individual risk before use during lactation.

To request Mirena, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

The primary alternative to Mirena is the copper intrauterine device, which provides non‑hormonal contraception. Mirena offers hormonal benefits such as reduced menstrual bleeding and relief of endometriosis‑related pain, whereas copper IUDs may increase menstrual flow. Both are highly effective for up to five years, but choice depends on patient preference, tolerance of hormonal effects, and specific clinical indications.

Mirena should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures. Healthcare providers should handle the IUS with sterile technique during insertion and keep it in a clean, dry environment until use.

Mirena is inserted into the uterine cavity by a trained clinician using a specialized inserter. The procedure is performed in a clinical setting after confirming the patient is not pregnant and that the uterine cavity is suitable. Once placed, the device remains in situ for up to five years, after which it should be removed or replaced.

Serious risks include uterine perforation during insertion, device expulsion, pelvic inflammatory infection, and ectopic pregnancy if contraception fails. Rarely, severe allergic reactions or thromboembolic events may occur. Patients should seek immediate medical attention for severe abdominal pain, fever, abnormal vaginal bleeding, or signs of infection.

Mirena is contraindicated in women who are pregnant, have a known or suspected uterine malignancy, active pelvic infection, unexplained vaginal bleeding, or significant uterine anomalies such as bicornuate uterus. It should also be avoided in patients with a history of severe allergic reaction to levonorgestrel or any component of the device.